Alberto-Culver appointments
This article was originally published in The Rose Sheet
Executive Summary
Company appoints three new directors to its board following its November break from Sally Beauty, Alberto-Culver states Dec. 7. Kay Napier, Thomas Dattilo and George Fotiades will join the board along with President and CEO Jim Marino, firm says. The three appointees will replace A.G. Atwater, William Wirtz and Howard Bernick, who retired from the board following completion of the separation transaction, and John Miller, who joined the new board of Sally Beauty Holdings. Alberto-Culver completed its separation from Sally Beauty Nov. 16; the entities are now two separate, publicly traded companies. In December, the firm announced a reorganization plan meant to "right-size" the company (1"The Rose Sheet" Dec. 4, 2006, In Brief)...
You may also be interested in...
Alberto-Culver “right-sizes”
Two marketing units will be combined into one as part of a company-wide reorganization following the firm's separation from Sally Beauty, it announces Dec. 1. In addition, certain international services will either be outsourced or combined into regional offices. The company also plans to reduce its workforce of 3,800 employees by approximately 90 and close its Dallas, Texas manufacturing facility by the end of 2007. The reorganization represents a "right-sizing" of the company, taking into consideration "services we were maintaining in support of Sally and corporate activities that could be scaled back to match the needs of a smaller company," according to Jim Marino, president and CEO. The firm expects to incur restructuring charges of approximately $13 mil. and $3 mil. in Q1 and Q2 of 2007, respectively. The reorganization and all financial charges related to it are expected to be "substantially completed" by the end of Q2 2007. Alberto-Culver broke from Sally Beauty in November (1"The Rose Sheet" Nov. 27, 2006, In Brief)...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.